281 related articles for article (PubMed ID: 31550054)
1. Compassionate Use of Cefiderocol in the Treatment of an Intraabdominal Infection Due to Multidrug-Resistant Pseudomonas aeruginosa: A Case Report.
Stevens RW; Clancy M
Pharmacotherapy; 2019 Nov; 39(11):1113-1118. PubMed ID: 31550054
[TBL] [Abstract][Full Text] [Related]
2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
3. Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa.
Edgeworth JD; Merante D; Patel S; Young C; Jones P; Vithlani S; Wyncoll D; Roberts P; Jones A; Den Nagata T; Ariyasu M; Livermore DM; Beale R
Clin Infect Dis; 2019 May; 68(11):1932-1934. PubMed ID: 30418554
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human Plasma Pharmacokinetics.
Matsumoto S; Singley CM; Hoover J; Nakamura R; Echols R; Rittenhouse S; Tsuji M; Yamano Y
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630178
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamics of cefiderocol, a novel siderophore cephalosporin, in a Pseudomonas aeruginosa neutropenic murine thigh model.
Ghazi IM; Monogue ML; Tsuji M; Nicolau DP
Int J Antimicrob Agents; 2018 Feb; 51(2):206-212. PubMed ID: 29111435
[TBL] [Abstract][Full Text] [Related]
6. Case Commentary: the Need for Cefiderocol Is Clear, but Are the Supporting Clinical Data?
Shields RK
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015037
[TBL] [Abstract][Full Text] [Related]
7. Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug-Resistant Gram-Negative Pathogens.
Abdul-Mutakabbir JC; Alosaimy S; Morrisette T; Kebriaei R; Rybak MJ
Pharmacotherapy; 2020 Dec; 40(12):1228-1247. PubMed ID: 33068441
[TBL] [Abstract][Full Text] [Related]
8. Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program.
Satlin MJ; Simner PJ; Slover CM; Yamano Y; Nagata TD; Portsmouth S
Antimicrob Agents Chemother; 2023 Jul; 67(7):e0019423. PubMed ID: 37347188
[TBL] [Abstract][Full Text] [Related]
9. Treatment of carbapenem-resistant
Canton R; Doi Y; Simner PJ
Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1077-1094. PubMed ID: 35502603
[TBL] [Abstract][Full Text] [Related]
10. Compassionate use of a novel β-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report.
Dubey D; Roy M; Shah TH; Bano N; Kulshrestha V; Mitra S; Sangwan P; Dubey M; Imran A; Jain B; Velmurugan A; Bakthavatchalam YD; Veeraraghavan B
Ann Clin Microbiol Antimicrob; 2023 Jul; 22(1):55. PubMed ID: 37408075
[TBL] [Abstract][Full Text] [Related]
11.
Karlowsky JA; Walkty AJ; Baxter MR; Adam HJ; Lagacé-Wiens PRS; Schweizer F; Bay D; Lynch JP; Mulvey MR; Zhanel GG
Microbiol Spectr; 2022 Aug; 10(4):e0172422. PubMed ID: 35758747
[TBL] [Abstract][Full Text] [Related]
12. Cefiderocol: A Siderophore Cephalosporin.
El-Lababidi RM; Rizk JG
Ann Pharmacother; 2020 Dec; 54(12):1215-1231. PubMed ID: 32522005
[TBL] [Abstract][Full Text] [Related]
13. Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
Vickery SB; McClain D; Wargo KA
Pharmacotherapy; 2016 Oct; 36(10):e154-e159. PubMed ID: 27522066
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
[TBL] [Abstract][Full Text] [Related]
15. Stability and low induction propensity of cefiderocol against chromosomal AmpC β-lactamases of Pseudomonas aeruginosa and Enterobacter cloacae.
Ito A; Nishikawa T; Ota M; Ito-Horiyama T; Ishibashi N; Sato T; Tsuji M; Yamano Y
J Antimicrob Chemother; 2018 Nov; 73(11):3049-3052. PubMed ID: 30188999
[TBL] [Abstract][Full Text] [Related]
16. Recurrent neurosurgical site infection by extensively drug-resistant
Bavaro DF; Romanelli F; Stolfa S; Belati A; Diella L; Ronga L; Fico C; Monno L; Mosca A; Saracino A
Infect Dis (Lond); 2021 Mar; 53(3):206-211. PubMed ID: 33295821
[TBL] [Abstract][Full Text] [Related]
17. The emergence of cefiderocol resistance in
Teran N; Egge SL; Phe K; Baptista RP; Tam VH; Miller WR
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0100923. PubMed ID: 38063509
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Compassionate Use of Cefiderocol To Treat Chronic Osteomyelitis Caused by Extensively Drug-Resistant Pseudomonas aeruginosa and Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae in a Pediatric Patient.
Alamarat ZI; Babic J; Tran TT; Wootton SH; Dinh AQ; Miller WR; Hanson B; Wanger A; Gary JL; Arias CA; Pérez N
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31871075
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa causing urinary, intra-abdominal and lower respiratory tract infections in intensive care units in Portugal: The STEP multicenter study.
García-Fernández S; García-Castillo M; Melo-Cristino J; Pinto MF; Gonçalves E; Alves V; Vieira AR; Ramalheira E; Sancho L; Diogo J; Ferreira R; Silva D; Chaves C; Pássaro L; Paixão L; Cantón R;
Int J Antimicrob Agents; 2020 Mar; 55(3):105887. PubMed ID: 31926283
[TBL] [Abstract][Full Text] [Related]
20. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme.
Stone GG; Newell P; Gasink LB; Broadhurst H; Wardman A; Yates K; Chen Z; Song J; Chow JW
J Antimicrob Chemother; 2018 Sep; 73(9):2519-2523. PubMed ID: 29912399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
